A clinical trial in patients with obesity and DM showed that chronic administration of a long-acting form of FGF21 caused a marked elevation of circulating adiponectin levels and an obvious reduction in blood levels of total and LDL-cholesterol [7]. Here, FGF21 is linked to obesity disorder.